AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04583046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost inhalation
Description: When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply iloprost inhalation for iloprost group and measure ABGA at the time of 20 min after iloprost inhalation has finished (T2).
Study NCT02552186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caliper measurement
Description: Clinical caliper measurements will be taken and used to calculate the Clinical PI
Study NCT02504723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate
Description: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
Study NCT01480687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofibrate
Description: 100 mg/day
Study NCT03763578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: Natural herbal product
Study NCT03763578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Natural herbal product
Study NCT00772759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199 Turbuhaler®
Description: 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
Study NCT00772759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Turbuhaler®
Description: single and multiple (o.d. for 12 days)
Study NCT00654108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.
Study NCT00654108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15-pCTB
Description: Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
Study NCT00654108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Description: Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
Study NCT02235324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT02235324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT02235324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02235324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01549743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib plus Rebamipide
Description: Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide
Study NCT01370057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoraco-lumbo-sacral Orthosis
Description: Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
Study NCT00516724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study NCT00516724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection
Study NCT00516724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: Oral
Study NCT00516724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous injection
Study NCT00516724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Intravenous injection
Study NCT02180789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS
Description: oral
Study NCT01282073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil, low dose steroid
Description: Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks
Study NCT03829865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution esophageal manometry
Description: High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
Study NCT01282073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin, low dose steroid
Description: Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks
Study NCT05314660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38 % silver diamine fluoride
Description: Application of 38% SDF on carious dentine lesions.
Study NCT05314660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative technique
Description: Hand excavation of carious dentine followed by application of Glass ionomer
Study NCT05314660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra conservative dentistry
Description: Removal of soft dentine and enlarging of cavity to control bio film
Study NCT01145950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101
Description: Etanercept 25mg, single dose
Study NCT01145950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel
Description: Etanercept 25mg, single dose
Study NCT01116284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revision of gastric bypass
Description: A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
Study NCT01597739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527
Description: Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
Study NCT01597739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule; route=oral use; twice daily.
Study NCT03235050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 low dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT03235050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 mid dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT03235050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 high dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT03235050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT03235050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study NCT02232087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study NCT02232087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study NCT00784524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic large multivalent immunogen breast cancer vaccine
Description: Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
Study NCT02232087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow, Room Temperature Injection
Description: The room temperature local anesthetic agent will be administered by slow infiltration.
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid, Room Temperature Injection
Description: The room temperature local anesthetic agent will be administered by rapid infiltration.
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow, Warm Temperature Injection
Description: The warmed local anesthetic agent will be administered by slow infiltration.
Study NCT02711839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercial diabetic formula
Description: The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
Study NCT02711839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White sweet potato formula
Description: The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid, Warm Temperature Injection
Description: The warmed local anesthetic agent will be administered by rapid infiltration.
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buffered Injection
Description: One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
Study NCT02823002 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Buffered Injection
Description: One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
Study NCT02823002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
Study NCT03294759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio ACL
Description: Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
Study NCT03294759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Normal ACL reconstruction technique with either patella or hamstring autograft
Study NCT02232087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study NCT01133522 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01133522 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT02989545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal Tape
Study NCT03266666 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WellnessRX Lifestyle Change Classes
Description: Lifestyle change classes on nutrition, physical activity, and stress management.
Study NCT03266666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thrive Market Grocery Credits (4x$25 each)
Description: Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
Study NCT00304317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
Study NCT00304317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
Study NCT00784524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
Study NCT00844636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharp needle
Study NCT00844636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blunt needles
Study NCT02875938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous music and reading lyrics
Description: music with sung lyrics simultaneously with silent reading of the lyrics.
Study NCT04347226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
Study NCT02851433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total anaesthesia and postoperative inhaled sedation with Sevoflurane
Study NCT02851433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anaesthesia with Propofol.
Study NCT01182389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic VT Ablation
Description: Robotic VT Ablation
Study NCT05628558 — intervention group
Intervention type: DRUG
Intervention: Desmopressin
Description: The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care.
Study NCT03349827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exploratory laparoscopy or laparotomy
Description: Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
Study NCT03349827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
Study NCT03349827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
Study NCT03349827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, once daily, day 1 to day 21.
Study NCT02936687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOS Inhibition
Description: NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
Study NCT02936687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-1 Inhibition
Description: ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
Study NCT02936687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOS Inhibition Placebo
Description: Saline will be infused at the same rate and quantity as the corresponding drug visit.
Study NCT02936687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI
Description: A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
Study NCT02936687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Catheter
Description: A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
Study NCT02936687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
Study NCT02823002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
Study NCT02875938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming with music
Description: priming with music and sung lyrics followed by reading of the lyrics.
Study NCT02875938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: control condition using reading materials without music.
Study NCT02565069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartoFinder™ Device with CARTO® 3 System V5 Navigation
Description: Ablation treatment
Study NCT02823002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate
Study NCT00276419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
Study NCT00276419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
Study NCT02667743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Micelles for Injection
Study NCT01968343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy.
Description: Subjects receive 22 sessions of cognitive-behavioral therapy.
Study NCT01968343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy.
Description: Subjects receive 22 sessions of supportive therapy.
Study NCT03461718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Experimental arm for sedation.
Study NCT03461718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
Study NCT03461718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
Study NCT02667743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Injection
Study NCT02667743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02667743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02810080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Control Ventilation
Description: Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software
Study NCT02810080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Control Ventilation
Description: Manual control ventilation using ZOLL 731 ventilator
Study NCT01128790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: 4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
Study NCT03461718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Part of standard sedation regimen
Study NCT01128790 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: 4 cycles x 5mins blood pressure cuff inflation to 10mmHg
Study NCT02304913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglossal acupuncture
Study NCT00688597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvoglustat
Description: Powder in a bottle for dissolution in water for oral administration
Study NCT01923636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: detection of CMV
Description: Clinical, radiological and laboratory (virological and immunological) standardized reports
Study NCT03681756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WALK
Description: Walking program
Study NCT03817684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: Drug BPN14770